Skip Navigation

Neuro-Oncology 2008 10(3):244-253; doi:10.1215/15228517-2008-016
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mizobuchi, Y.
Right arrow Articles by Nagahiro, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mizobuchi, Y.
Right arrow Articles by Nagahiro, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright 2008 by the Society for Neuro-Oncology

REIC/Dkk-3 induces cell death in human malignant glioma

Yoshifumi Mizobuchi, Kazuhito Matsuzaki, Kazuyuki Kuwayama, Keiko Kitazato, Hideo Mure, Teruyoshi Kageji and Shinji Nagahiro

Department of Neurosurgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Kuramoto-cho, Tokushima, Japan

Address all correspondence to Yoshifumi Mizobuchi, Department of Neurosurgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, 3-18-15, Kuramoto-cho, Tokushima, Japan 770-8503 (mizo{at}yj8.so-net.ne.jp).


   Abstract

The progression of glioma to more malignant phenotypes results from the stepwise accumulation of genetic alterations and the consequent disruption of the apoptotic pathway and augmentation of survival signaling. REIC/Dkk-3, a member of the human Dickkopf (Dkk) family, plays a role as a suppressor of the growth of several human cancers; however, to date it has not been identified in brain tumors. We compared the gene and protein expression of REIC/Dkk-3 in human malignant glioma and normal brain tissues using quantitative real-time PCR, Western blotting, and immunohistochemistry. We also performed small interfering REIC/Dkk-3 (siREIC/Dkk-3) knockdown and REIC/Dkk-3 overexpression experiments to examine the role of REIC/Dkk-3 in human malignant glioma cells in vitro. In brain tissue from patients with malignant glioma, the gene and protein expression of REIC/Dkk-3 was lower than in normal brain tissue and was related to the malignancy grade. In the primary glioblastoma cell line, REIC/Dkk-3 transfection led to apoptosis owing to the activation of phosphorylated JUN, caspase-9, and caspase-3 and the reduction of β-catenin; in REIC/Dkk-3 knockdown experiments, cell growth was augmented. Our results suggest that REIC/Dkk-3 regulates the growth and survival of these cells in a caspase-dependent and -independent way via modification of the Wnt signaling pathway. Our work is the first documentation that the gene and protein expression of REIC/Dkk-3 is down-regulated in human malignant glioma. Our demonstration of the mechanisms underlying REIC/Dkk-3-induced cell death indicates that REIC/Dkk-3 plays a pivotal role in the biology of human malignant glioma and suggests that REIC/Dkk-3 is a promising candidate for molecular target therapy.

Keywords: apoptosis, β-catenin, caspase, malignant glioma, REIC/Dkk-3

Received April 19, 2007; Accepted October 3, 2007


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Neuro OncologyHome page
H. Mure, K. Matsuzaki, K. T. Kitazato, Y. Mizobuchi, K. Kuwayama, T. Kageji, and S. Nagahiro
Akt2 and Akt3 play a pivotal role in malignant gliomas
Neuro Oncology, December 21, 2009; (2009) nop026v1.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.